Nuclear Medicine Diagnostics Global Market Report 2024

The nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $6.57 billion in 2023 to $7.34 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%. Historical growth can be linked to advancements in medical imaging, rising chronic disease rates, trends in an aging population, clinical applications in oncology, and the pursuit of diagnostic accuracy and precision.

The nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $11.31 billion in 2028 at a compound annual growth rate (CAGR) of 11.4%. Forecasted growth is spurred by expanding neurology applications, integrated imaging modalities, precision medicine, theranostics demand, and global disease eradication efforts. Key trends involve decentralized radiopharmacy, increased nuclear medicine use in neurology, radiomics, collaborative R&D, and emphasized radiation safety.

The anticipated growth of the nuclear medicine diagnostics market is driven by a rising demand for these diagnostic techniques. Nuclear medicine utilizes radioactive substances within the body for diagnosing illnesses and for targeted removal of diseased or damaged organs and tissues during treatment. The applications of nuclear medicine diagnostics are predominantly in radiation and other life-saving treatments. The increasing demand for these diagnostics is attributed to their advantages, including accurate results and enhanced treatment decision-making capabilities. As reported in April 2022 by the World Nuclear Association, a UK-based international organization advocating for nuclear power, the annual number of nuclear medicine treatments surpasses 40 million, with the demand for radioisotopes witnessing a yearly growth rate of up to 5%. Notably, over 90% of procedures involving radioisotopes in medicine are conducted in more than 10,000 hospitals worldwide. This surge in demand underscores the pivotal role of nuclear medicine diagnostics, contributing to the anticipated growth of the nuclear medicine diagnostics market.

The anticipated growth of the nuclear medicine diagnostics market is strongly influenced by the increasing prevalence of cancer. Cancer, characterized by the uncontrolled growth and spread of abnormal cells forming tumors, represents a group of diseases. Nuclear medicine diagnostics play a crucial role in the detection, staging, and monitoring of various types of cancer, utilizing radioactive substances detectable by specialized cameras. This process generates detailed images of internal structures and functions of organs and tissues. As of January 2023, reports from the American Cancer Society Inc., a US-based voluntary health organization, indicated 606,520 cancer fatalities. By 2021, it is projected that there will be 1.9 million new cancer cases diagnosed and 608,570 cancer deaths. This substantial increase in cancer cases underscores the significance of nuclear medicine diagnostics in addressing the challenges posed by cancer, thus driving the growth of the nuclear medicine diagnostics market.

Prominent companies in the nuclear medicine diagnostics market are strategically focusing on the introduction of advanced solutions, particularly advanced medical technologies, to establish a competitive advantage. Advanced medical technologies represent cutting-edge innovations within the medical field, aimed at improving patient outcomes, elevating the standard of care, and fostering overall health improvement. An illustrative example is Gleneagles Hospital, a Malaysia-based company providing medical and healthcare services. In August 2023, the hospital introduced a Nuclear Medicine Unit, showcasing its commitment to advanced medical technologies. This specialized unit, equipped with state-of-the-art technology and staffed by highly skilled professionals, is designed to facilitate early detection, diagnosis, and treatment of diseases through nuclear medicine imaging techniques. Such initiatives by major companies underscore the industry's dedication to advancing technology and enhancing medical capabilities within the nuclear medicine diagnostics market.

Major companies in the nuclear medicine diagnostics market are actively pursuing strategic partnerships as a key approach to securing a competitive edge. Strategic partnerships involve collaborative efforts between two or more entities with the goal of achieving mutually advantageous objectives by combining resources and expertise. A noteworthy example occurred in June 2023, where RLS Inc., a US-based nuclear medicine provider, entered into a strategic partnership with SOFIE, a US-based molecular imaging company. Through this collaboration, RLS Inc. aims to enhance the distribution of nuclear medicine doses to patients, hospitals, teaching institutions, and doctors, thereby improving the overall continuum of care for patients. This strategic partnership will streamline patient dose preparation, capitalizing on the accredited radiopharmacy network and expertise of both entities involved. Such initiatives underscore the industry's commitment to fostering collaboration and leveraging collective strengths to drive advancements in the nuclear medicine diagnostics market.

In January 2022, Eckert & Ziegler, a Germany-based provider of isotope technology for medical, scientific, and industrial applications, successfully acquired Tecnonuclear SA for an undisclosed sum. This strategic acquisition positions Eckert & Ziegler to broaden its footprint and enhance essential healthcare services in Brazil and across South America. Tecnonuclear SA, an Argentina-based specialist in nuclear medicine, brings valuable expertise and resources to strengthen Eckert & Ziegler's presence in the region, aligning with the company's commitment to advancing isotope technology for medical applications.

Major companies operating in the nuclear medicine diagnostics market report are Siemens AG, Bayer Aktiengesellschaft, Novartis AG, GE Healthcare Technologies Inc., Perkin Elmer Inc., Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Cardinal Health Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion (Canada) Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited, Actinium Pharmaceuticals Inc., Jubilant DraxImage Inc., PharmaLogic Holdings Corp., Institute of Isotopes Co. Ltd., Global Medical Solutions LLC, Theragnostics Ltd., Sirona Complete Care, Nordic Nanovector ASA, Eczacıbaşı-Monrol Nuclear Products Co.

North America was the largest region in the nuclear medicine diagnostics market in 2023. The regions covered in the nuclear medicine diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nuclear medicine diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of nuclear medicine diagnostics encompass SPECT radiopharmaceuticals and PET radiopharmaceuticals. SPECT Radiopharmaceuticals, or single-photon emission computerized tomography, pertain to gamma-ray tomographic imaging techniques employed in the field of nuclear medicine. These methods find application in diverse medical areas such as cardiology, thyroid, neurology, oncology, among others. End-users of these diagnostic technologies include hospitals, diagnostic centers, and research institutes.

The nuclear medicine diagnostics market research report is one of a series of new reports that provides nuclear medicine diagnostics market statistics, including nuclear medicine diagnostics industry global market size, regional shares, competitors with nuclear medicine diagnostics market share, detailed nuclear medicine diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the nuclear medicine diagnostics industry. This nuclear medicine diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nuclear medicine diagnostics market consists of sales of renal scan, bone scan, gallium scan, heart scan, brain scan and breast scan diagnostics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.